Bertero E, Maack C. Metabolic remodeling in heart failure. Nat Rev Cardiol. 2018;15:457–70.

CAS  PubMed  Google Scholar 

Perrino C, Naga Prasad SV, Mao L, Noma T, Yan Z, Kim HS, et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest. 2006;116:1547–60.

CAS  PubMed  PubMed Central  Google Scholar 

Zhou SS, Jin JP, Wang JQ, Zhang ZG, Freedman JH, Zheng Y, et al. miRNAs in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacol Sin. 2018;39:1073–84.

CAS  PubMed  PubMed Central  Google Scholar 

Dzau VJ, Hodgkinson CP. RNA therapeutics for the cardiovascular system. Circulation. 2024;149:707–16.

CAS  PubMed  Google Scholar 

Xiao M, Li J, Li W, Wang Y, Wu F, Xi Y, et al. MicroRNAs activate gene transcription epigenetically as an enhancer trigger. RNA Biol. 2017;14:1326–34.

PubMed  Google Scholar 

Liang Y, Zou Q, Yu W. Steering against wind: a new network of namiRNAs and enhancers. Genomics Proteom Bioinforma. 2017;15:331–7.

CAS  Google Scholar 

Li J, Salvador AM, Li G, Valkov N, Ziegler O, Yeri A, et al. Mir-30d regulates cardiac remodeling by intracellular and paracrine signaling. Circ Res. 2021;128:e1–e23.

CAS  PubMed  Google Scholar 

Gao L, Qiu F, Cao H, Li H, Dai G, Ma T, et al. Therapeutic delivery of microRNA-125a-5p oligonucleotides improves recovery from myocardial ischemia/reperfusion injury in mice and swine. Theranostics. 2023;13:685–703.

CAS  PubMed  PubMed Central  Google Scholar 

Ramanujam D, Schön AP, Beck C, Vaccarello P, Felician G, Dueck A, et al. MicroRNA-21-dependent macrophage-to-fibroblast signaling determines the cardiac response to pressure overload. Circulation. 2021;143:1513–25.

CAS  PubMed  PubMed Central  Google Scholar 

Li G, Shao Y, Guo HC, Zhi Y, Qiao B, Ma K, et al. MicroRNA-27b-3p down-regulates FGF1 and aggravates pathological cardiac remodelling. Cardiovasc Res. 2022;118:2139–51.

CAS  PubMed  Google Scholar 

Liu X, Li H, Hastings MH, Xiao C, Damilano F, Platt C, et al. miR-222 inhibits pathological cardiac hypertrophy and heart failure. Cardiovasc Res. 2024;120:262–72.

PubMed  Google Scholar 

Zeng N, Huang YQ, Yan YM, Hu ZQ, Zhang Z, Feng JX, et al. Diverging targets mediate the pathological role of miR-199a-5p and miR-199a-3p by promoting cardiac hypertrophy and fibrosis. Mol Ther Nucleic Acids. 2021;26:1035–50.

CAS  PubMed  PubMed Central  Google Scholar 

Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32:453–61.

CAS  PubMed  PubMed Central  Google Scholar 

Zhang C, Huo ST, Wu Z, Chen L, Wen C, Chen H, et al. Rapid development of targeting circRNAs in cardiovascular diseases. Mol Ther Nucleic Acids. 2020;21:568–76.

CAS  PubMed  PubMed Central  Google Scholar 

Liu X, Abraham JM, Cheng Y, Wang Z, Wang Z, Zhang G, et al. Synthetic circular RNA functions as a miR-21 sponge to suppress gastric carcinoma cell proliferation. Mol Ther Nucleic Acids. 2018;13:312–21.

CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Ma K, Cheng Y, Abraham JM, Liu X, Ke X, et al. Synthetic circular multi-miR sponge simultaneously inhibits miR-21 and miR-93 in esophageal carcinoma. Lab Invest. 2019;99:1442–53.

PubMed  Google Scholar 

Jost I, Shalamova LA, Gerresheim GK, Niepmann M, Bindereif A, Rossbach O. Functional sequestration of microRNA-122 from Hepatitis C Virus by circular RNA sponges. RNA Biol. 2018;15:1032–9.

PubMed  PubMed Central  Google Scholar 

Lavenniah A, Luu TDA, Li YP, Lim TB, Jiang J, Ackers-Johnson M, et al. Engineered circular RNA sponges act as miRNA inhibitors to attenuate pressure overload-induced cardiac hypertrophy. Mol Ther. 2020;28:1506–17.

CAS  PubMed  PubMed Central  Google Scholar 

Tang CM, Liu FZ, Zhu JN, Fu YH, Lin QX, Deng CY, et al. Myocyte-specific enhancer factor 2C: a novel target gene of miR-214-3p in suppressing angiotensin II-induced cardiomyocyte hypertrophy. Sci Rep. 2016;6:36146.

CAS  PubMed  PubMed Central  Google Scholar 

Liang JN, Zou X, Fang XH, Xu JD, Xiao Z, Zhu JN, et al. The Smad3-miR-29b/miR-29c axis mediates the protective effect of macrophage migration inhibitory factor against cardiac fibrosis. Biochim Biophys Acta Mol Basis Dis. 2019;1865:2441–50.

CAS  PubMed  Google Scholar 

Li H, Xu JD, Fang XH, Zhu JN, Yang J, Pan R, et al. Circular RNA circRNA_000203 aggravates cardiac hypertrophy via suppressing miR-26b-5p and miR-140-3p binding to Gata4. Cardiovasc Res. 2020;116:1323–34.

CAS  PubMed  Google Scholar 

Lewis-Israeli YR, Wasserman AH, Gabalski MA, Volmert BD, Ming Y, Ball KA, et al. Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease. Nat Commun. 2021;12:5142.

CAS  PubMed  PubMed Central  Google Scholar 

Yang J, Lei W, Xiao Y, Tan S, Yang J, Lin Y, et al. Generation of human vascularized and chambered cardiac organoids for cardiac disease modelling and drug evaluation. Cell Prolif. 2024;57:e13631.

CAS  PubMed  PubMed Central  Google Scholar 

Huang S, Zou X, Zhu JN, Fu YH, Lin QX, Liang YY, et al. Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy. J Cell Mol Med. 2015;19:608–19.

CAS  PubMed  PubMed Central  Google Scholar 

Huang C, Shan G. What happens at or after transcription: Insights into circRNA biogenesis and function. Transcription. 2015;6:61–64.

CAS  PubMed  PubMed Central  Google Scholar 

Ye Z, Jin H, Qian Q. Argonaute 2: a novel rising star in cancer research. J Cancer. 2015;6:877–82.

CAS  PubMed  PubMed Central  Google Scholar 

Segers VFM, Brutsaert DL, De Keulenaer GW. Cardiac remodeling: endothelial cells have more to say than just NO. Front Physiol. 2018;9:382.

PubMed  PubMed Central  Google Scholar 

Talman V, Kivelä R. Cardiomyocyte-endothelial cell interactions in cardiac remodeling and regeneration. Front Cardiovasc Med. 2018;5:101.

PubMed  PubMed Central  Google Scholar 

Vishnoi A, Rani S. miRNA biogenesis and regulation of diseases: an updated overview. Methods Mol Biol. 2023;2595:1–12.

CAS  PubMed  Google Scholar 

Couzin J. MicroRNAs make big impression in disease after disease. Science. 2008;319:1782–4.

CAS  PubMed  Google Scholar 

Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet. 2022;38:613–26.

CAS  PubMed  Google Scholar 

Ho PTB, Clark IM, Le LTT. MicroRNA-based diagnosis and therapy. Int J Mol Sci. 2022;23:7167.

CAS  PubMed  PubMed Central  Google Scholar 

Seyhan AA. Trials and tribulations of microRNA therapeutics. Int J Mol Sci. 2024;25:1469.

CAS  PubMed  PubMed Central  Google Scholar 

Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA. 2010;16:2043–50.

CAS  PubMed  PubMed Central  Google Scholar 

Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4:721–6.

CAS  PubMed  Google Scholar 

Li D, Zhang J, Li J. Role of miRNA sponges in hepatocellular carcinoma. Clin Chim Acta. 2020;500:10–19.

CAS  PubMed  Google Scholar 

Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.